文献速递免疫规划传染病防控与疫情报告

三价gC2/gD2/gE2疫苗对HSV-2免疫逃逸域抗体应答优于自然感染

A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.
PubMed 文献 · Vaccine · 2018-12-12

该研究关注预防和治疗生殖器疱疹的疫苗开发,策略为阻断HSV-2糖蛋白D介导的病毒入胞及糖蛋白C和E的免疫逃逸域。研究显示自然感染人及豚鼠产生的抗体结合gC2但通常不能阻断其免疫逃逸域,而以CpG和铝佐剂免疫gC2亚单位抗原可产生阻断免疫逃逸域的抗体。结果表明gC2免疫逃逸域在感染中为弱抗原,但作为疫苗免疫原配合佐剂可诱导阻断性抗体。

要点

  • 自然感染产生的抗gC2抗体多不能阻断其免疫逃逸域。
  • gC2亚单位抗原配合CpG和铝佐剂可诱导阻断免疫逃逸域的抗体。
  • 该三价疫苗策略聚焦阻断HSV-2入胞与免疫逃逸。

核心结论

  • gC2免疫逃逸域在自然感染中为弱抗原,但作为疫苗免疫原配合佐剂可产生阻断免疫逃逸域的抗体。

研究设计与样本

  • 研究检测了人自然感染和豚鼠阴道接种HSV-2后产生的抗体,并免疫naïve或既往HSV-2感染豚鼠评估gC2亚单位抗原配合CpG和铝佐剂的抗体应答。

主要发现

  • 人自然感染或豚鼠阴道接种HSV-2产生的抗体结合gC2,但通常不能阻断该糖蛋白上的免疫逃逸域。
  • 以gC2亚单位抗原配合CpG和铝佐剂免疫naïve或既往HSV-2感染豚鼠,可产生阻断免疫逃逸相关域的抗体。

临床怎么用

  • 提示gC2免疫逃逸域可作为HSV-2疫苗免疫原,配合CpG和铝佐剂诱导阻断性抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines for prevention and treatment of genital herpes are high public health priorities. Our approach towards vaccine development is to focus on blocking virus entry mediated by herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) and to prevent the virus from evading complement and antibody attack by blocking the immune evasion domains on HSV-2 glycoproteins C (gC2) and E (gE2), respectively. HSV-2 gC2 and gE2 are expressed on the virion envelope and infected cell surface where they are potential targets of antibodies that bind and block their immune evasion activities. We demonstrate that antibodies produced during natural infection in humans or intravaginal inoculation in guinea pigs bind to gC2 but generally fail to block the immune evasion domains on this glycoprotein. In contrast, immunization of naïve or previously HSV-2-infected guinea pigs with gC2 subunit antigen administered with CpG and alum as adjuvants produces antibodies that block domains involved in immune evasion. These results indicate that immune evasion domains on gC2 are weak antigens during infection, yet when used as vaccine immunogens with adjuvants the antigens produce antibodies that block immune evasion domains.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hook LM, Awasthi S, Dubin J, et al. A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection. Vaccine. 2018. PMID: 30551986. doi:10.1016/j.vaccine.2018.11.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。